Literature DB >> 23555367

Effects of antiplatelet agents and other factors on neointimal proliferation in iliac artery stenting: intravascular ultrasound analysis.

Hisao Kumakura1, Hiroyoshi Kanai, Yoshihiro Araki, Akira Koizumi, Shu Kasama, Hiroyuki Sumino, Shuichi Ichikawa.   

Abstract

OBJECTIVE: To use intravascular ultrasound to investigate the effects of antiplatelet agents and other factors on neointimal proliferation after stent implantation for iliac artery stenosis. PATIENTS AND METHODS: The subjects were 109 patients with peripheral arterial disease who underwent stent implantation in the iliac artery. Intravascular ultrasound was performed to evaluate lesion area, stent dilatation and neointimal proliferation before, just after, and six months after stenting. Multiple regression analysis was performed to examine the relationship of the neointimal proliferation rate with antiplatelet agents and other factors.
RESULTS: At the time of stent implantation, a Palmaz stent resulted in a significant increase in lumen area compared with a Wallstent (p < 0.05). Six months later, self-expanding Wallstent and Luminexx stents showed a significant increase in the stent-lumen area (p < 0.05). The neointimal proliferation rate showed a significant negative correlation with beraprost and cilostazol (p < 0.05) and a significant positive correlation with serum creatinine (p < 0.01). There was no significant difference in the vessel lumen area including the proliferated intima among the three stents.
CONCLUSION: Suppression of neointimal proliferation can be achieved with beraprost or cilostazol whereas renal dysfunction may increase neointimal proliferation following stent implantation in iliac artery lesions.

Entities:  

Keywords:  beraprost; iliac artery; neointimal proliferation; peripheral arterial disease; stent implantation

Year:  2009        PMID: 23555367      PMCID: PMC3611847          DOI: 10.3400/avd.AVDoa08022

Source DB:  PubMed          Journal:  Ann Vasc Dis        ISSN: 1881-641X


  31 in total

1.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

2.  Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group.

Authors:  M Lièvre; S Morand; B Besse; J N Fiessinger; J P Boissel
Journal:  Circulation       Date:  2000-07-25       Impact factor: 29.690

3.  Effects of beraprost sodium (Dorner) in patients with diabetes mellitus complicated by chronic arterial obstruction.

Authors:  Takayoshi Toyota; Shinichi Oikawa
Journal:  Angiology       Date:  2002 Jan-Feb       Impact factor: 3.619

4.  Intravascular ultrasound scanning improves long-term patency of iliac lesions treated with balloon angioplasty and primary stenting.

Authors:  Clifford J Buckley; Frank R Arko; Shirley Lee; Mark Mettauer; Danny Little; Marvin Atkins; Larry G Manning; Donald E Patterson
Journal:  J Vasc Surg       Date:  2002-02       Impact factor: 4.268

5.  Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways.

Authors:  Kazuo Niwano; Masashi Arai; Koichi Tomaru; Tsuyoshi Uchiyama; Yoshio Ohyama; Masahiko Kurabayashi
Journal:  Circ Res       Date:  2003-08-14       Impact factor: 17.367

6.  Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).

Authors:  Seung-Whan Lee; Seong-Wook Park; Young-Hak Kim; Sung-Cheol Yun; Duk-Woo Park; Cheol Whan Lee; Myeong-Ki Hong; Hyun-Sook Kim; Jae-Ki Ko; Jae-Hyeong Park; Jae-Hwan Lee; Si Wan Choi; In-Whan Seong; Yoon Haeng Cho; Nae-Hee Lee; June Hong Kim; Kook-Jin Chun; Seung-Jung Park
Journal:  J Am Coll Cardiol       Date:  2008-03-25       Impact factor: 24.094

Review 7.  Percutaneous coronary intervention in chronic kidney disease patients.

Authors:  George M Tadros; Charles A Herzog
Journal:  J Nephrol       Date:  2004 May-Jun       Impact factor: 3.902

8.  Small aggregates of platelets can be detected sensitively by a flow cytometer equipped with an imaging device: mechanisms of epinephrine-induced aggregation and antiplatelet effects of beraprost.

Authors:  Kaneo Satoh; Yutaka Yatomi; Fumio Kubota; Yukio Ozaki
Journal:  Cytometry       Date:  2002-08-01

9.  Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.

Authors:  Young-Hoon Jeong; Myeong-Ki Hong; Cheol Whan Lee; Duk-Woo Park; Young-Hak Kim; Jae-Joong Kim; Seong-Wook Park; Seung-Jung Park
Journal:  Int J Cardiol       Date:  2007-05-22       Impact factor: 4.164

10.  Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty.

Authors:  M Isogaya; N Yamada; H Koike; Y Ueno; H Kumagai; Y Ochi; S Okazaki; S Nishio
Journal:  J Cardiovasc Pharmacol       Date:  1995-06       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.